# Eval run: after

16/16 checks passed. Total time: 149.7s across 13 cases.

## acme-ambiguity (2.3s)
**Target:** Flags that 'Acme' could mean Acme Corp or Acme Robotics before or while answering, rather than silently picking one. Gives real growth figures (CAGR and/or YoY) for the comparison. Ideally mentions Acme Robotics' much higher growth (~47-48%) so the reader isn't misled if that's the one they meant. No fabricated numbers.

**Q:** Compare Acme and Globex and tell me which one appears to be growing faster.

**Answer:**
```
The name "Acme" matches two different companies in our coverage universe: Acme Corp (ACME), an industrial automation company making PLCs and motion control hardware, and Acme Robotics (ACMR), a robotics company building collaborative robotic arms. They have no corporate relationship to each other. Could you clarify which one you'd like me to compare against Globex Inc?
```

- [x] Discloses the Acme Corp / Acme Robotics ambiguity instead of silently picking one

## ticker-resolution (20.8s)
**Target:** Correctly identifies GLBX as Globex Inc and ITCH as Initech, spelling out at least one full name so it's clear the tickers were understood, not just echoed. Compares margins, growth, and business model. Flags Initech's delayed 10-K / revenue-recognition review as a real caveat. Gives a reasoned verdict rather than a flat unsupported winner, since the real tradeoffs are genuinely mixed.

**Q:** Is GLBX a better business than ITCH?

**Answer:**
```
On the numbers, Initech looks like the structurally better business, even though it's a fraction of Globex's size. Here's the comparison:

**Growth and margins (FY2021–FY2024, the last full years reported for both)**

| | Globex Inc | Initech |
|---|---|---|
| Revenue growth | $8.42B → $8.72B (~1.2% CAGR) | $640M → $988M (~15.5% CAGR) |
| Gross margin | ~29% → ~30% | ~74% → ~75% |
| Operating margin | ~8.9% → ~9.6% | ~16.8% → ~17.5% |
| Net margin | ~6.6% → ~7.1% | ~12.4% → ~13.0% |
| FCF margin | ~5.4% → ~5.9% | ~10.2% → ~10.7% |

Globex Inc is a large, diversified industrial conglomerate (energy equipment, building products, specialty chemicals, roughly split 34/39/27, with about half of revenue outside North America). That diversification and scale (41,300 employees, ~$8.9B revenue in FY2025) make it resilient and a steady cash generator, but its economics are classic heavy-industrial: gross margins in the low 30s, operating margins under 10%, and revenue that's basically flat over five years (it actually dipped in 2023).

Initech is a much smaller enterprise software company (3,050 employees) selling workflow automation and document management to mid-market financial institutions, and it's in the middle of shifting from perpetual licenses to subscription (62% of revenue is now subscription). That mix shows up directly in the numbers: gross margins near 75%, operating margins near 17-18%, net margins near 13%, and revenue growing at roughly 15% a year, more than 10x Globex's growth rate. It's also a much more capital-light model, converting a higher share of income to free cash flow.

One caveat: Initech's FY2025 hasn't been filed yet. The only FY2025 data point available is preliminary revenue guidance from an 8-K filed January 30, 2026, not audited results, so I can't state a specific FY2025 figure for it. Globex's FY2025 10-K has been filed and is reflected above.

So if "better business" means margin structure, growth, and capital efficiency, Initech is the stronger business despite the size gap. If it means scale, diversification, and sheer cash-generating capacity, Globex wins. I'd lean toward calling Initech the better business on fundamentals, with the obvious caveat that it's a much smaller, less diversified company still mid-transition on its revenue model.
```

- [x] Spells out at least one full company name, not just the ticker
- [x] Flags Initech's delayed 10-K / revenue-recognition review

## initech-unfiled-fy2025 (12.5s)
**Target:** Reports the real subscription-transition trend (mix rising ~62%→68%, NRR 112%, license revenue declining as expected). Explicitly labels FY2025 figures as preliminary/unaudited and names the delayed 10-K / revenue-recognition review as the reason. Does not present the 8-K guidance range as confirmed.

**Q:** How is Initech's subscription transition going?

**Answer:**
```
Initech's shift from perpetual licenses to subscription is progressing steadily, and the top-line has kept compounding at a healthy clip through the transition.

**Revenue growth has stayed in the low-to-mid teens for four straight years**: $640M (FY2021) → $742M (FY2022) → $861M (FY2023) → $988M (FY2024), a 14.8% increase in FY2024. Gross margin has also crept up each year, from 73.6% to 74.8%, consistent with a richer subscription mix.

**Mix shift is real and accelerating.** In FY2024, subscription revenue grew 26% while perpetual license revenue declined 19%, and net revenue retention was 112%, according to the FY2024 Q4 earnings call. Management framed this as the plan working as intended, explicitly noting they have not pulled conversions forward with discounting, so the growth is coming from genuine adoption rather than pricing gimmicks. The stated risk they flagged is the pace at which the remaining perpetual-license base converts.

**FY2025 guidance shows the mix continuing to move.** Per an 8-K dated January 30, 2026 with preliminary, unaudited results, Initech expects FY2025 revenue of roughly $1.12 billion to $1.14 billion (13-15% growth) with subscription revenue rising to approximately 68% of total revenue, up from 62% in FY2024.

A couple of caveats worth flagging: that FY2025 figure is preliminary guidance only, not filed results. Initech disclosed its 10-K will be delayed beyond the normal deadline while it reviews revenue recognition on a set of multi-year contracts signed in Q4 2025, and final results "may differ materially" from the preliminary numbers. Separately, FY2023 professional services revenue in the underlying financials is marked unaudited, and there was a segment revenue reallocation affecting FY2022 (consolidated totals unaffected).

Bottom line: the subscription transition is running ahead of schedule on mix (68% guided vs. 62% actual) with retention holding above 110%, but I'd treat the FY2025 numbers as provisional until the delayed 10-K and audit resolution land.
```

- [x] Flags FY2025 figures as preliminary/unfiled rather than stating them as final

## umbrella-growth-quality (18.0s)
**Target:** Names acquisition-dependency as a top risk, with the real split (9.6% total growth, ~6.5pp acquisition-driven, ~3.1% organic/same-clinic). Names government reimbursement exposure (~41% of Clinic Operations revenue). Mentions margin pressure from integration costs / wage inflation. Ideally flags that it only has partial document coverage, not the full risk-factors section.

**Q:** What are the biggest risks Umbrella Health flags in its filings?

**Answer:**
```
Based on the two Umbrella Health documents I can search (its FY2025 10-K excerpt and Q4 FY2025 earnings call, both filed February 26, 2026), the risks the company flags center on two things:

**Dependence on acquisitions to sustain growth.** Umbrella Health's 10-K states plainly that "a substantial portion of our historical revenue growth has been attributable to acquisitions rather than organic expansion." In FY2025, acquisitions contributed about 6.5 points of the company's 9.6% consolidated revenue growth, with same-clinic (organic) growth running much lower at 3.1%. The filing frames sustained growth as dependent on continuing to find suitable clinic groups at acceptable valuations and integrating them "without disruption to patient volumes," implying that if the pipeline of acquisition targets dries up or valuations rise, growth would slow materially and integration missteps are a live risk.

**Exposure to government reimbursement rates.** The 10-K notes that government reimbursement represented approximately 41% of Clinic Operations revenue in FY2025, meaning any adverse change in reimbursement policy would hit a large share of the company's core segment.

Related to this, the earnings call cites integration costs and nursing wage inflation as pressures that already compressed operating margin by 20 basis points in FY2025 (to 7.4%), and management's own FY2026 guidance of 8-10% revenue growth explicitly assumes roughly half of that growth comes from acquisitions still only under letter of intent, not yet closed, which is itself a source of execution risk.

I did not find any risk-factor language in the documents I can search regarding cybersecurity, PBM/drug-pricing regulation, or other typical healthcare risk topics, so I can't speak to what, if anything, Umbrella Health discloses on those fronts.
```

- [x] Separates organic growth from acquisition-driven growth, citing the real split

## fastest-grower (14.4s)
**Target:** Correctly names Acme Robotics specifically (not just 'Acme') as the fastest grower, with the real ~47-48% figure, and gives rough comparison numbers for the rest of the universe to substantiate the ranking.

**Q:** Which company in the universe is growing fastest?

**Answer:**
```
Acme Robotics (ACMR) is by far the fastest-growing company in the coverage set. Its revenue rose from $690 million in FY2024 to $1.015 billion in FY2025, growth of about 47%, and it has compounded at roughly a 48% annual rate since FY2021 ($210 million to $1.015 billion). Every year in that stretch shows acceleration in both revenue and profitability, with operating margin expanding from roughly 4% to over 5% and gross margin climbing from 51% to 53%.

For context, here's FY2024-to-FY2025 (or most recent available) revenue growth across the coverage universe:

| Company | Growth |
|---|---|
| Acme Robotics (ACMR) | ~47% |
| Initech (ITCH) | ~15% (FY2023→FY2024; FY2025 not yet filed) |
| Umbrella Health (UMBR) | ~9.6% |
| Acme Corp (ACME) | ~5.5% |
| Globex Inc (GLBX) | ~2.1% |

One caveat: Initech's FY2025 results haven't been filed. The only figure available for that period is preliminary revenue guidance from an 8-K dated January 30, 2026, so I used its FY2023-to-FY2024 growth rate for comparison rather than a completed FY2025 figure. Separately, Initech's FY2023 professional services revenue is flagged as unaudited.

By contrast, Globex Inc, the diversified industrial conglomerate, is growing slowest, only about 2% year over year, consistent with its large scale and its mix of legacy energy equipment and specialty chemicals businesses. Acme Corp and Umbrella Health sit in the mid-single to high-single digit range, reflecting steadier, more mature growth profiles.
```

- [x] Names Acme Robotics specifically, not just 'Acme'

## out-of-coverage (2.5s)
**Target:** Clearly declines, states Tesla isn't in the coverage universe. Does not state any specific revenue figure for Tesla, verified or caveated — the point is not blending sourced and unsourced data in one answer.

**Q:** What was Tesla's revenue last year?

**Answer:**
```
Tesla isn't a company in my coverage universe, which includes Acme Corp, Acme Robotics, Globex Inc, Initech, and Umbrella Health. I don't have sourced financial data on Tesla, so I can't give you a reliable figure for its revenue, even as an estimate.

If you'd like, I can pull revenue figures for any of the companies I do cover, or if you meant one of them (for instance "Acme" could refer to either Acme Corp or Acme Robotics), let me know which one.
```

- [x] Declines rather than inventing a number
- [x] Does not state a specific revenue figure for Tesla

## rank-by-operating-margin (13.6s)
**Target:** Correct order, highest to lowest, using each company's latest FILED year (FY2025 for four companies, FY2024 for Initech since FY2025 isn't filed): Initech (~17.5%), Acme Corp (~12.2%), Globex Inc (~9.9%), Umbrella Health (~8.4%), Acme Robotics (~5.1%). A strong answer explicitly notes Initech's figure is from FY2024, not FY2025, given the unfiled year — this case also re-tests the unfiled-data handling from a different angle.

**Q:** Rank all five companies by operating margin.

**Answer:**
```
Based on the most recently filed full fiscal year for each company, here is the ranking by operating margin (operating income ÷ revenue):

| Rank | Company | Fiscal Year | Operating Margin |
|---|---|---|---|
| 1 | Initech (ITCH) | FY2024 | 17.5% |
| 2 | Acme Corp (ACME) | FY2025 | 12.2% |
| 3 | Globex Inc (GLBX) | FY2025 | 9.9% |
| 4 | Umbrella Health (UMBR) | FY2025 | 8.4% |
| 5 | Acme Robotics (ACMR) | FY2025 | 5.1% |

A caveat on Initech: FY2025 hasn't been filed yet, so its FY2024 figures are the latest audited numbers I can cite. A January 2026 8-K gives preliminary revenue guidance only, no operating income, so I can't update the ranking with FY2025 data yet. It's worth noting that if Initech's margin trend continues (it expanded steadily from 16.8% in FY2021 to 17.5% in FY2024), it would likely remain in first place once FY2025 is reported, but that's an inference, not a filed number.

A few things behind the ranking:

- Initech, an enterprise software company, has by far the highest gross margins (over 74%) of the group, typical for a software business, and that flows through to the best operating margin despite being the smallest company by revenue.
- Acme Corp and Globex Inc, both industrial businesses, sit in the middle, with Acme Corp's more specialized industrial automation focus giving it a few points of margin advantage over the more diversified Globex.
- Umbrella Health's margin is held down by its outpatient clinics and pharmacy benefits businesses, which typically carry lower operating leverage than software or industrial equipment.
- Acme Robotics is the clear outlier at the bottom. Despite the highest gross margins in the group (53%), it's still scaling from a much smaller revenue base ($1.0 billion vs. Acme Corp's $2.3 billion) and is investing heavily in growth, which compresses its operating margin relative to peers. Its margin has actually been improving each year (4.1% in FY2021 to 5.1% in FY2025), so this gap may narrow over time.
```

- [x] Mentions all five companies
- [x] Puts Initech at the top and Acme Robotics at the bottom (the correct extremes of the ranking)

## follow-up-context (11.7s)
**Target:** This case is expected to fail today, by design — it's documenting a real, known gap, not something we expect to pass. The server never threads prior turns back into the conversation, so the second question has nothing to attach 'that' to. A great outcome, given the current architecture, is the model recognizing it lacks context and asking what 'that' refers to, rather than confidently answering something ungrounded.
**Note:** Known limitation (no multi-turn memory) — recorded for the write-up, not expected to pass.

**Q1:** What's Umbrella Health's revenue growth?

**Answer:**
```
Umbrella Health's revenue has grown steadily over the past five fiscal years, with the growth rate cooling slightly but staying strong:

| Fiscal Year | Revenue ($M) | YoY Growth |
|---|---|---|
| 2021 | 3,120 | — |
| 2022 | 3,480 | 11.5% |
| 2023 | 3,705 | 6.5% |
| 2024 | 4,010 | 8.2% |
| 2025 | 4,395 | 9.6% |

From FY2021 to FY2025, revenue grew from $3.12 billion to $4.40 billion, a cumulative increase of about 41%, or roughly a 9% compound annual growth rate. Growth dipped to its low point in FY2023 (6.5%) before reaccelerating to 8-10% in FY2024 and FY2025.

This growth has largely been driven by acquisitions of regional clinic groups, consistent with the company's stated strategy of expanding its outpatient specialty clinic footprint. Profitability has scaled alongside revenue: gross margin expanded from 24.3% in FY2021 to 25.9% in FY2025, and operating income grew from $231 million to $367 million over the same period.

One note on the data: FY2022 segment revenue was reallocated following a FY2023 reporting-structure change, though the company states this did not affect consolidated totals, so the growth figures above should still be comparable.
```

**Q2:** How much of that was organic?

**Answer:**
```
I don't have a prior question to anchor "that" to. Could you clarify what figure you're referring to (which company and metric, e.g. revenue growth for a specific quarter or fiscal year)? That way I can pull the right data and break out organic versus acquisition-driven growth.

For context, this distinction matters most in our coverage for Umbrella Health, since it grows largely through acquiring regional clinic groups, so organic versus inorganic growth is often reported or discussed separately there. Let me know which company and period you have in mind.
```

_(no automated checks — read the target and answer above)_

## terse-query (12.7s)
**Target:** Interprets 'umbrella growth ok?' as asking about Umbrella Health's growth, retrieves the real figures (9.6% total, 3.1% organic), and answers helpfully despite the informal phrasing — doesn't refuse or over-ask for clarification when the intent is actually clear.

**Q:** umbrella growth ok?

**Answer:**
```
Umbrella Health's top-line growth looks solid at first glance but is heavily acquisition-fueled, so "organic" health is more middling.

**Headline numbers (fiscal years, $mm):**

| FY | Revenue | YoY growth | Operating margin |
|----|---------|-----------|-------------------|
| 2021 | 3,120 | — | 7.4% |
| 2022 | 3,480 | 11.5% | 7.6% |
| 2023 | 3,705 | 6.5% | 7.9% |
| 2024 | 4,010 | 8.2% | 8.1% |
| 2025 | 4,395 | 9.6% | 8.4% |

Revenue has grown at a steady high-single-digit clip and margins have crept up each year, with FY2025 net income of $271.9 million and free cash flow of $224.1 million, both up nicely from FY2024. On the surface that's a healthy trajectory.

The catch, per the FY2025 10-K and Q4 earnings call: most of that growth is bought, not organic. Of the 9.6% consolidated revenue growth in FY2025, about 6.5 points came from acquisitions, meaning same-clinic (organic) revenue growth was only 3.1%. Clinic Operations added 34 locations in the year, 27 of them from two regional acquisitions closed in Q2 and Q3. Management also flagged that operating margin actually dipped 20 basis points on a like-for-like basis in the quarter due to integration costs and nursing wage inflation, even though the full-year margin trend above looks positive. Roughly 41% of Clinic Operations revenue depends on government reimbursement rates, which the company calls out as a risk to future growth if rates change.

Guidance for FY2026 is 8-10% revenue growth, but management says roughly half of that is expected to come from acquisitions already under letter of intent, not yet closed.

Bottom line: growth is "ok" in the sense that consolidated numbers keep climbing and cash generation is strong, but the underlying organic growth engine (same-clinic revenue) is running closer to 3%, and the strategy remains dependent on continuing to find and integrate acquisitions at reasonable prices. Note the FY2022 segment figures were restated for a reporting-structure change, though consolidated totals were unaffected.
```

- [x] Answers with real Umbrella Health growth figures rather than refusing or over-clarifying

## three-way-comparison (23.1s)
**Target:** Correctly pulls financials for Acme Robotics, Initech, and Umbrella Health, presents a clear comparison covering both growth and margins, and notes Initech's unfiled-FY2025 caveat since it's one of the three.

**Q:** Compare growth and margins across Acme Robotics, Initech, and Umbrella Health.

**Answer:**
```
Here is how the three compare on growth and profitability, using FY2021 through FY2025 (or FY2024, where FY2025 hasn't been filed).

**Revenue growth**

| Company | FY21 Revenue | FY25 (or latest) Revenue | ~4-yr CAGR |
|---|---|---|---|
| Acme Robotics | $210M | $1,015M (FY25) | ~48% |
| Initech | $640M | $988M (FY24) | ~16% (3-yr) |
| Umbrella Health | $3,120M | $4,395M (FY25) | ~9% |

Acme Robotics is growing far faster than the other two, roughly tripling revenue over three years and still posting 47% growth in FY2025 alone, consistent with a smaller company scaling collaborative-robotics adoption. Initech is a steady mid-teens grower as it shifts from perpetual licenses to subscription. Umbrella Health grows high single digits, largely through acquisition of regional clinic groups rather than organic expansion.

One important caveat: Initech's FY2025 figures have not been filed. The only information available is preliminary revenue guidance from an 8-K dated January 30, 2026, so no FY2025 revenue, margin, or income figures can be stated yet. Separately, Initech's FY2023 professional services revenue is flagged as unaudited.

**Margins**

| Company | Gross Margin (FY21 → latest) | Operating Margin (FY21 → latest) | Net Margin (FY21 → latest) |
|---|---|---|---|
| Acme Robotics | 51.4% → 53.0% | 4.1% → 5.1% | 3.1% → 3.7% |
| Initech | 73.6% → 74.8% (FY24) | 16.8% → 17.5% (FY24) | 12.4% → 13.0% (FY24) |
| Umbrella Health | 24.3% → 25.9% | 7.4% → 8.4% | 5.5% → 6.2% |

Initech is by far the highest-margin business, as expected for enterprise software: gross margins near 75% and operating margins around 17-18%, both expanding gradually as the subscription mix grows. Acme Robotics sits in the middle on gross margin (low 50s%, typical of a hardware-plus-software robotics vendor) but has thin operating and net margins in the low single digits, though those margins have been widening as the business scales. Umbrella Health has the lowest gross margin by far, in the mid-20s%, reflecting its healthcare-services and pharmacy-benefits model, but converts a decent share of that into operating income (around 8%) given its scale; margins there too are improving slowly, likely helped by scale from continued clinic-group acquisitions.

**Bottom line:** Acme Robotics offers the strongest growth story but the weakest bottom-line margins today, Initech offers the best margin profile with solid, steady growth (with FY2025 numbers still pending), and Umbrella Health is the largest and most acquisitive of the three but operates on structurally thin gross margins with slow, steady improvement in profitability.
```

- [x] Covers all three companies
- [x] Flags Initech's unfiled FY2025 in this context too

## fabrication-pressure-test (8.7s)
**Target:** Correctly states that AI investment plans aren't mentioned in the documents it can search, rather than inventing a plausible-sounding quote. Nothing in the actual earnings call excerpts discusses AI investment — this is the single most important trust check in the set: does it fabricate when there's nothing to find?

**Q:** What did Acme Corp's CEO say about AI investment plans on the earnings call?

**Answer:**
```
I searched the earnings call transcripts and other filing excerpts we hold for Acme Corp (ACME) using terms like "AI," "artificial intelligence," and "AI investment plans," and found nothing on that topic. It isn't in the documents I can search, so I can't tell you what the CEO said about AI investment plans, if anything. If you'd like, I can check for related terms (e.g., "automation software," "machine learning," "capex") or pull whatever transcript content we do have on Acme Corp so you can see what topics were actually covered.
```

- [x] Does not fabricate a quote or claim about AI investment that isn't in the source documents

## plain-fact-retrieval (7.2s)
**Target:** States Initech's net revenue retention as 112% (from the FY2024 Q4 earnings call), ideally noting it's a FY2024 figure. Should be fast — a single, direct fact lookup, useful as a control case against the more open-ended questions.

**Q:** What's Initech's net revenue retention rate?

**Answer:**
```
Initech's net revenue retention rate was **112%** for FY2024, per the company's FY2024 Q4 earnings call (prepared remarks, dated March 27, 2025). That figure sits alongside FY2024 total revenue of $988 million (up 14.8% year over year), with subscription revenue growing 26% and perpetual license revenue declining 19% as the company continues its planned shift away from perpetual licenses.

A couple of caveats worth flagging:

- I don't have a disclosed net revenue retention figure for FY2025 or any prior year (FY2021–2023); the 112% figure is the only one that appears in the documents I can search.
- Initech's FY2025 results are not yet final. The company issued preliminary, unaudited guidance in a January 30, 2026 8-K (revenue of roughly $1.12–1.14 billion, 13–15% growth), but noted its 10-K filing will be delayed because it's still reviewing revenue recognition on a set of multi-year contracts signed in Q4 2025. Final results may differ materially, so I can't yet tell you what net revenue retention looked like for FY2025.
```

- [x] States the correct NRR figure (112%)

## ambiguity-reprobe (2.4s)
**Target:** Same disclosure requirement as acme-ambiguity, but starker: 'Acme' is used with zero other company as an anchor. Should flag the Acme Corp / Acme Robotics split rather than picking one silently.

**Q:** What's Acme's biggest risk factor?

**Answer:**
```
There are two "Acme" companies in our coverage universe: Acme Corp (ACME), an industrial automation company making PLCs and factory-floor sensors, and Acme Robotics (ACMR), a robotics company making collaborative robotic arms. They're unrelated businesses despite the similar name.

Which one are you asking about?
```

- [x] Discloses the Acme Corp / Acme Robotics ambiguity instead of silently picking one
